Syndax Pharmaceuticals licenses selective histone deacetylase inhibitor MS-275
News | 04. 13. 2007
Syndax Pharmaceuticals, Inc. announced today that it has entered into an exclusive licensing agreement with Bayer Schering Pharma AG for the acquisition of worldwide rights to the selective histone deacetylase inhibitor (HDACi) MS-275, which becomes known as SNDX-275. Under the terms of the agreement, Syndax will develop and commercialize the compound, while Bayer Schering Pharma will receive upfront and milestone payments. The HDACi becomes Syndax’s lead product candidate to be developed in combination with other oncology therapies. Financial terms of the agreement were not announced.
© 2023 Pappas Capital, LLC. ALL RIGHTS RESERVED.